Galderma Group
Galderma Group is a Swiss specialized dermatology company dedicated to delivering medical and aesthetic solutions for skin health worldwide. The enterprise organizes its global operational activities into three primary business categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Its commercial portfolio includes injectable neuromodulators and dermal fillers such as Dysport and Restylane, alongside skincare brands Cetaphil and specialized prescription acne treatments. Principal revenue drivers consist of global wholesale sales of aesthetic products, premium skincare lines, and prescription dermatological treatments to healthcare professionals, pharmacies, and retail channels. The company holds a prominent market position globally within aesthetic medicine and specialized dermatological skin care products. Galderma Group is headquartered in Zug, Switzerland, and its ordinary shares are publicly traded on the SIX Swiss Exchange under ticker symbol GALD.
90 of the funds FundTelligence covers report a position in Galderma Group.
- Legal name
- Galderma Group AG
- Sector
- Health Care
- Country
- Switzerland
- Funds holding it
- 90
Funds holding Galderma Group
- Vontobel European Equity — Vontobel · 4.58 % (full portfolio disclosed, February 2026)
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 3.9 % (partially disclosed portfolio, September 2026)
- Vontobel Global Equity — Vontobel · 3.27 % (full portfolio disclosed, February 2026)
- GS Global Future Generations Equity Portfolio — Goldman Sachs · 2.68 % (largest positions only, October 2026)
- Nordea Global Consumer Trends — Nordea Funds · 2.66 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 2.18 % (full portfolio disclosed, October 2026)
- Handelsbanken Europa — Handelsbanken · 1.93 % (full portfolio disclosed, October 2026)
- Eika Global — Eika · 1.81 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 90 funds holding it.